Our Blog

A Setback for NHS Access – But Re:Cognition Health Offers Hope for Alzheimer’s

Turning Setback Into Progress This week’s decision by NICE (the National Institute for Health and Care Excellence) to reject funding for two groundbreaking Alzheimer’s drugs Leqembi™ (lecanemab) […]

Patient Story

“The entire experience of participating in the clinical trial has been exceptional. The team at Re:Cognition Health genuinely prioritises the wellbeing of their patients. Their understanding and […]

Hearing Loss and Dementia: Understanding the Link and Why Early Intervention Matters

Dr Steve Allder, Consultant Neurologist at Re:Cognition Health, recently shared his insights with Medical News Today following the release of a significant new study that shines a […]

A Pivotal Time in Alzheimer’s Treatment: Slowing the Disease Before It Progresses

Dr Emer MacSweeney, CEO of Re:Cognition Health, has shared with Healthcare World why recent developments in Alzheimer’s treatment mark a major breakthrough in neurology. Alzheimer’s disease, long […]

New Alzheimer’s Medications

Dr Emer MacSweeney, CEO and Medical Director at Re:Cognition Health shared her excitement with the Daily Express about the groundbreaking new Alzheimer’s drugs that are now available […]

Re:Cognition Health Brings Groundbreaking Alzheimer’s Treatment Kisunla™ to Private Patients

Re:Cognition Health is proud to announce the launch of Kisunla™ (donanemab), a revolutionary Alzheimer’s treatment, for private patients at our specialist clinics. This follows the success of […]